Key Points
- BioNTech CEO Ugur Sahin sold 24,000 shares at an average price of $95.86, generating approximately $2.3 million. The transaction was conducted under a pre-arranged Rule 10b5-1 trading plan, leaving him with 63,209 shares.
- The sale extends a series of insider transactions, with Sahin selling more than 350,000 shares across multiple trades since September 21.
- BioNTech reported weaker quarterly results, including a $2.53 loss per share and revenue of $122.31 million, while analysts maintained a generally positive outlook with a “Moderate Buy” consensus and an average price target of $125.69.
BioNTech SE Sponsored ADR (NASDAQ:BNTX - Get Free Report) CEO Ugur Sahin sold 24,000 shares of the firm's stock in a transaction that occurred on Wednesday, October 7th. The shares were sold at an average price of $95.86, for a total transaction of $2,300,640.00. Following the completion of the transaction, the chief executive officer directly owned 63,209 shares in the company, valued at approximately $6,059,214.74. The trade was a 27.52% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Ugur Sahin also recently made the following trade(s):
- On Tuesday, October 6th, Ugur Sahin sold 21,000 shares of BioNTech stock. The shares were sold at an average price of $96.81, for a total transaction of $2,033,010.00.
- On Monday, October 5th, Ugur Sahin sold 72,000 shares of BioNTech stock. The shares were sold at an average price of $97.23, for a total transaction of $7,000,560.00.
- On Thursday, October 1st, Ugur Sahin sold 17,000 shares of BioNTech stock. The shares were sold at an average price of $97.46, for a total value of $1,656,820.00.
- On Wednesday, September 30th, Ugur Sahin sold 32,000 shares of BioNTech stock. The stock was sold at an average price of $98.12, for a total value of $3,139,840.00.
- On Monday, September 28th, Ugur Sahin sold 34,000 shares of BioNTech stock. The stock was sold at an average price of $98.47, for a total value of $3,347,980.00.
- On Friday, September 25th, Ugur Sahin sold 27,000 shares of BioNTech stock. The stock was sold at an average price of $98.69, for a total value of $2,664,630.00.
- On Thursday, September 24th, Ugur Sahin sold 39,000 shares of BioNTech stock. The shares were sold at an average price of $98.99, for a total value of $3,860,610.00.
- On Wednesday, September 23rd, Ugur Sahin sold 30,000 shares of BioNTech stock. The shares were sold at an average price of $99.40, for a total value of $2,982,000.00.
- On Tuesday, September 22nd, Ugur Sahin sold 46,000 shares of BioNTech stock. The stock was sold at an average price of $100.72, for a total value of $4,633,120.00.
- On Monday, September 21st, Ugur Sahin sold 33,000 shares of BioNTech stock. The stock was sold at an average price of $97.81, for a total value of $3,227,730.00.
BioNTech Price Performance
BioNTech stock opened at $95.25 on Thursday. The company has a current ratio of 7.85, a quick ratio of 7.80 and a debt-to-equity ratio of 0.01. The firm has a market capitalization of $24.09 billion, a P/E ratio of -12.16 and a beta of 1.25. The business has a 50-day moving average of $99.06 and a 200-day moving average of $95.14. BioNTech SE Sponsored ADR has a 1 year low of $79.52 and a 1 year high of $124.00.
BioNTech (NASDAQ:BNTX - Get Free Report) last announced its quarterly earnings results on Tuesday, August 4th. The company reported ($2.53) earnings per share for the quarter, missing analysts' consensus estimates of ($2.40) by ($0.13). BioNTech had a negative net margin of 63.54% and a negative return on equity of 6.86%. The firm had revenue of $122.31 million during the quarter, compared to analyst estimates of $180.18 million. During the same quarter in the prior year, the business earned ($1.60) earnings per share. The business's revenue was down 59.5% on a year-over-year basis. On average, equities analysts anticipate that BioNTech SE Sponsored ADR will post -6.37 EPS for the current year.
Analyst Ratings Changes
Several equities research analysts have weighed in on the stock. Berenberg Bank set a $140.00 target price on shares of BioNTech in a report on Wednesday, September 16th. BMO Capital Markets cut shares of BioNTech from an "outperform" rating to a "market perform" rating and lowered their price objective for the company from $128.00 to $105.00 in a research report on Tuesday, September 8th. Citigroup dropped their price objective on BioNTech from $130.00 to $125.00 and set a "buy" rating on the stock in a research note on Wednesday, August 5th. Canaccord Genuity Group reduced their target price on BioNTech from $142.00 to $136.00 and set a "buy" rating on the stock in a report on Monday, August 31st. Finally, Morgan Stanley reduced their target price on BioNTech from $115.00 to $114.00 and set an "overweight" rating on the stock in a report on Wednesday. One research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $125.69.
Get Our Latest Stock Report on BioNTech
Institutional Inflows and Outflows
A number of institutional investors have recently bought and sold shares of BNTX. Hsbc Holdings PLC bought a new position in shares of BioNTech during the fourth quarter worth about $4,969,000. Bank of America Corp DE lifted its stake in BioNTech by 22.6% in the 1st quarter. Bank of America Corp DE now owns 903,029 shares of the company's stock valued at $80,261,000 after acquiring an additional 166,432 shares in the last quarter. Amundi lifted its stake in BioNTech by 24.5% in the 1st quarter. Amundi now owns 129,513 shares of the company's stock valued at $11,511,000 after acquiring an additional 25,506 shares in the last quarter. Headlands Technologies LLC acquired a new position in BioNTech during the 2nd quarter worth approximately $2,520,000. Finally, Flossbach Von Storch SE acquired a new position in BioNTech during the 2nd quarter worth approximately $207,142,000. Institutional investors own 15.52% of the company's stock.
BioNTech Company Profile
(
Get Free Report)
BioNTech SE is a biotechnology company headquartered in Mainz, Germany, focused on developing therapies and vaccines for cancer and other serious diseases. The company's research platform includes messenger RNA (mRNA), individualized cancer vaccines, immune-modulating therapies, cell therapies, and protein-based therapeutics.
BioNTech is best known for developing the Comirnaty COVID-19 vaccine in collaboration with Pfizer. Comirnaty uses mRNA technology to help stimulate an immune response against COVID-19 and has been distributed in markets around the world.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
